![]() |
||||||
|
![]() | Fusion Gene Summary |
![]() | Fusion Gene ORF analysis |
![]() | Fusion Genomic Features |
![]() | Fusion Protein Features |
![]() | Fusion Gene Sequence |
![]() | Fusion Gene PPI analysis |
![]() | Related Drugs |
![]() | Related Diseases |
Fusion gene:NXN-CAV1 (FusionGDB2 ID:HG64359TG857) |
Fusion Gene Summary for NXN-CAV1 |
![]() |
Fusion gene information | Fusion gene name: NXN-CAV1 | Fusion gene ID: hg64359tg857 | Hgene | Tgene | Gene symbol | NXN | CAV1 | Gene ID | 64359 | 857 |
Gene name | nucleoredoxin | caveolin 1 | |
Synonyms | NRX|RRS2|TRG-4 | BSCL3|CGL3|LCCNS|MSTP085|PPH3|VIP21 | |
Cytomap | ('NXN')('CAV1') 17p13.3 | 7q31.2 | |
Type of gene | protein-coding | protein-coding | |
Description | nucleoredoxinnucleoredoxin 1 | caveolin-1caveolin 1, caveolae protein, 22kDacell growth-inhibiting protein 32 | |
Modification date | 20200327 | 20200329 | |
UniProtAcc | . | . | |
Ensembl transtripts involved in fusion gene | ENST00000336868, ENST00000537628, ENST00000538650, ENST00000575801, ENST00000577098, | ||
Fusion gene scores | * DoF score | 16 X 13 X 11=2288 | 11 X 9 X 7=693 |
# samples | 23 | 14 | |
** MAII score | log2(23/2288*10)=-3.31438128583401 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0 | log2(14/693*10)=-2.30742852519225 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0 | |
Context | PubMed: NXN [Title/Abstract] AND CAV1 [Title/Abstract] AND fusion [Title/Abstract] | ||
Most frequent breakpoint | NXN(882559)-CAV1(116166579), # samples:1 | ||
Anticipated loss of major functional domain due to fusion event. | NXN-CAV1 seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF. NXN-CAV1 seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF. NXN-CAV1 seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF. NXN-CAV1 seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF. |
* DoF score (Degree of Frequency) = # partners X # break points X # cancer types ** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10) |
![]() |
Partner | Gene | GO ID | GO term | PubMed ID |
Tgene | CAV1 | GO:0009617 | response to bacterium | 24625804 |
Tgene | CAV1 | GO:0010875 | positive regulation of cholesterol efflux | 24576892 |
Tgene | CAV1 | GO:0030512 | negative regulation of transforming growth factor beta receptor signaling pathway | 25893292 |
Tgene | CAV1 | GO:0031295 | T cell costimulation | 17287217 |
Tgene | CAV1 | GO:0031623 | receptor internalization | 25893292 |
Tgene | CAV1 | GO:0032091 | negative regulation of protein binding | 16890161 |
Tgene | CAV1 | GO:0032570 | response to progesterone | 12388746 |
Tgene | CAV1 | GO:0033137 | negative regulation of peptidyl-serine phosphorylation | 18081315 |
Tgene | CAV1 | GO:0033138 | positive regulation of peptidyl-serine phosphorylation | 18081315 |
Tgene | CAV1 | GO:0043627 | response to estrogen | 12388746 |
Tgene | CAV1 | GO:0051480 | regulation of cytosolic calcium ion concentration | 19052258 |
Tgene | CAV1 | GO:0072584 | caveolin-mediated endocytosis | 19931615 |
Tgene | CAV1 | GO:1900027 | regulation of ruffle assembly | 24625804 |
Tgene | CAV1 | GO:2000535 | regulation of entry of bacterium into host cell | 24625804 |
![]() * Click on the image to open the UCSC genome browser with custom track showing this image in a new window. |
![]() |
![]() * Click on the image to open the UCSC genome browser with custom track showing this image in a new window. |
![]() |
![]() * All genome coordinats were lifted-over on hg19. * Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser. |
Source | Disease | Sample | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand |
ChimerDB4 | Non-Cancer | ERR315355 | NXN | chr17 | 882559 | - | CAV1 | chr7 | 116166579 | + |
Top |
Fusion Gene ORF analysis for NXN-CAV1 |
![]() * Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser. |
ORF | Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand |
5CDS-5UTR | ENST00000336868 | ENST00000393467 | NXN | chr17 | 882559 | - | CAV1 | chr7 | 116166579 | + |
5CDS-5UTR | ENST00000336868 | ENST00000393468 | NXN | chr17 | 882559 | - | CAV1 | chr7 | 116166579 | + |
5CDS-5UTR | ENST00000336868 | ENST00000405348 | NXN | chr17 | 882559 | - | CAV1 | chr7 | 116166579 | + |
5CDS-intron | ENST00000336868 | ENST00000393470 | NXN | chr17 | 882559 | - | CAV1 | chr7 | 116166579 | + |
In-frame | ENST00000336868 | ENST00000341049 | NXN | chr17 | 882559 | - | CAV1 | chr7 | 116166579 | + |
intron-3CDS | ENST00000537628 | ENST00000341049 | NXN | chr17 | 882559 | - | CAV1 | chr7 | 116166579 | + |
intron-3CDS | ENST00000538650 | ENST00000341049 | NXN | chr17 | 882559 | - | CAV1 | chr7 | 116166579 | + |
intron-3CDS | ENST00000575801 | ENST00000341049 | NXN | chr17 | 882559 | - | CAV1 | chr7 | 116166579 | + |
intron-3CDS | ENST00000577098 | ENST00000341049 | NXN | chr17 | 882559 | - | CAV1 | chr7 | 116166579 | + |
intron-5UTR | ENST00000537628 | ENST00000393467 | NXN | chr17 | 882559 | - | CAV1 | chr7 | 116166579 | + |
intron-5UTR | ENST00000537628 | ENST00000393468 | NXN | chr17 | 882559 | - | CAV1 | chr7 | 116166579 | + |
intron-5UTR | ENST00000537628 | ENST00000405348 | NXN | chr17 | 882559 | - | CAV1 | chr7 | 116166579 | + |
intron-5UTR | ENST00000538650 | ENST00000393467 | NXN | chr17 | 882559 | - | CAV1 | chr7 | 116166579 | + |
intron-5UTR | ENST00000538650 | ENST00000393468 | NXN | chr17 | 882559 | - | CAV1 | chr7 | 116166579 | + |
intron-5UTR | ENST00000538650 | ENST00000405348 | NXN | chr17 | 882559 | - | CAV1 | chr7 | 116166579 | + |
intron-5UTR | ENST00000575801 | ENST00000393467 | NXN | chr17 | 882559 | - | CAV1 | chr7 | 116166579 | + |
intron-5UTR | ENST00000575801 | ENST00000393468 | NXN | chr17 | 882559 | - | CAV1 | chr7 | 116166579 | + |
intron-5UTR | ENST00000575801 | ENST00000405348 | NXN | chr17 | 882559 | - | CAV1 | chr7 | 116166579 | + |
intron-5UTR | ENST00000577098 | ENST00000393467 | NXN | chr17 | 882559 | - | CAV1 | chr7 | 116166579 | + |
intron-5UTR | ENST00000577098 | ENST00000393468 | NXN | chr17 | 882559 | - | CAV1 | chr7 | 116166579 | + |
intron-5UTR | ENST00000577098 | ENST00000405348 | NXN | chr17 | 882559 | - | CAV1 | chr7 | 116166579 | + |
intron-intron | ENST00000537628 | ENST00000393470 | NXN | chr17 | 882559 | - | CAV1 | chr7 | 116166579 | + |
intron-intron | ENST00000538650 | ENST00000393470 | NXN | chr17 | 882559 | - | CAV1 | chr7 | 116166579 | + |
intron-intron | ENST00000575801 | ENST00000393470 | NXN | chr17 | 882559 | - | CAV1 | chr7 | 116166579 | + |
intron-intron | ENST00000577098 | ENST00000393470 | NXN | chr17 | 882559 | - | CAV1 | chr7 | 116166579 | + |
![]() |
Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand | Seq length (transcript) | BP loci (transcript) | Predicted start (transcript) | Predicted stop (transcript) | Seq length (amino acids) |
ENST00000336868 | NXN | chr17 | 882559 | - | ENST00000341049 | CAV1 | chr7 | 116166579 | + | 2848 | 452 | 8 | 958 | 316 |
![]() |
Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand | No-coding score | Coding score |
ENST00000336868 | ENST00000341049 | NXN | chr17 | 882559 | - | CAV1 | chr7 | 116166579 | + | 0.000624241 | 0.99937576 |
Top |
Fusion Genomic Features for NXN-CAV1 |
![]() |
Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand | 1-p | p (fusion gene breakpoint) |
NXN | chr17 | 882558 | - | CAV1 | chr7 | 116166578 | + | 5.53E-05 | 0.9999447 |
NXN | chr17 | 882558 | - | CAV1 | chr7 | 116166578 | + | 5.53E-05 | 0.9999447 |
![]() |
![]() |
![]() |
![]() |
Top |
Fusion Protein Features for NXN-CAV1 |
![]() Go to FGviewer search page for the most frequent breakpoint (https://ccsmweb.uth.edu/FGviewer/chr17:882559/chr7:116166579) - FGviewer provides the online visualization of the retention search of the protein functional features across DNA, RNA, protein, and pathological levels. - How to search 1. Put your fusion gene symbol. 2. Press the tab key until there will be shown the breakpoint information filled. 4. Go down and press 'Search' tab twice. 4. Go down to have the hyperlink of the search result. 5. Click the hyperlink. 6. See the FGviewer result for your fusion gene. |
![]() |
![]() |
Hgene | Tgene |
. | . |
FUNCTION: Transcriptional activator which is required for calcium-dependent dendritic growth and branching in cortical neurons. Recruits CREB-binding protein (CREBBP) to nuclear bodies. Component of the CREST-BRG1 complex, a multiprotein complex that regulates promoter activation by orchestrating a calcium-dependent release of a repressor complex and a recruitment of an activator complex. In resting neurons, transcription of the c-FOS promoter is inhibited by BRG1-dependent recruitment of a phospho-RB1-HDAC1 repressor complex. Upon calcium influx, RB1 is dephosphorylated by calcineurin, which leads to release of the repressor complex. At the same time, there is increased recruitment of CREBBP to the promoter by a CREST-dependent mechanism, which leads to transcriptional activation. The CREST-BRG1 complex also binds to the NR2B promoter, and activity-dependent induction of NR2B expression involves a release of HDAC1 and recruitment of CREBBP (By similarity). {ECO:0000250}. | FUNCTION: Transcriptional activator which is required for calcium-dependent dendritic growth and branching in cortical neurons. Recruits CREB-binding protein (CREBBP) to nuclear bodies. Component of the CREST-BRG1 complex, a multiprotein complex that regulates promoter activation by orchestrating a calcium-dependent release of a repressor complex and a recruitment of an activator complex. In resting neurons, transcription of the c-FOS promoter is inhibited by BRG1-dependent recruitment of a phospho-RB1-HDAC1 repressor complex. Upon calcium influx, RB1 is dephosphorylated by calcineurin, which leads to release of the repressor complex. At the same time, there is increased recruitment of CREBBP to the promoter by a CREST-dependent mechanism, which leads to transcriptional activation. The CREST-BRG1 complex also binds to the NR2B promoter, and activity-dependent induction of NR2B expression involves a release of HDAC1 and recruitment of CREBBP (By similarity). {ECO:0000250}. |
![]() * Minus value of BPloci means that the break pointn is located before the CDS. |
- In-frame and retained protein feature among the 13 regional features. |
Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Protein feature | Protein feature note |
Tgene | CAV1 | chr17:882559 | chr7:116166579 | ENST00000341049 | 0 | 3 | 105_125 | 10 | 179.0 | Intramembrane | Helical | |
Tgene | CAV1 | chr17:882559 | chr7:116166579 | ENST00000393467 | 0 | 2 | 105_125 | 0 | 148.0 | Intramembrane | Helical | |
Tgene | CAV1 | chr17:882559 | chr7:116166579 | ENST00000393468 | 0 | 3 | 105_125 | 0 | 148.0 | Intramembrane | Helical | |
Tgene | CAV1 | chr17:882559 | chr7:116166579 | ENST00000405348 | 0 | 3 | 105_125 | 0 | 148.0 | Intramembrane | Helical | |
Tgene | CAV1 | chr17:882559 | chr7:116166579 | ENST00000341049 | 0 | 3 | 131_142 | 10 | 179.0 | Region | Interacts with SPRY1%2C SPRY2%2C SPRY3 and SPRY4 | |
Tgene | CAV1 | chr17:882559 | chr7:116166579 | ENST00000341049 | 0 | 3 | 149_160 | 10 | 179.0 | Region | Interacts with SPRY1%2C SPRY2%2C and SPRY4 | |
Tgene | CAV1 | chr17:882559 | chr7:116166579 | ENST00000341049 | 0 | 3 | 167_178 | 10 | 179.0 | Region | Interacts with SPRY1%2C SPRY2%2C SPRY3 and SPRY4 | |
Tgene | CAV1 | chr17:882559 | chr7:116166579 | ENST00000393467 | 0 | 2 | 131_142 | 0 | 148.0 | Region | Interacts with SPRY1%2C SPRY2%2C SPRY3 and SPRY4 | |
Tgene | CAV1 | chr17:882559 | chr7:116166579 | ENST00000393467 | 0 | 2 | 149_160 | 0 | 148.0 | Region | Interacts with SPRY1%2C SPRY2%2C and SPRY4 | |
Tgene | CAV1 | chr17:882559 | chr7:116166579 | ENST00000393467 | 0 | 2 | 167_178 | 0 | 148.0 | Region | Interacts with SPRY1%2C SPRY2%2C SPRY3 and SPRY4 | |
Tgene | CAV1 | chr17:882559 | chr7:116166579 | ENST00000393467 | 0 | 2 | 2_94 | 0 | 148.0 | Region | Required for homooligomerization | |
Tgene | CAV1 | chr17:882559 | chr7:116166579 | ENST00000393468 | 0 | 3 | 131_142 | 0 | 148.0 | Region | Interacts with SPRY1%2C SPRY2%2C SPRY3 and SPRY4 | |
Tgene | CAV1 | chr17:882559 | chr7:116166579 | ENST00000393468 | 0 | 3 | 149_160 | 0 | 148.0 | Region | Interacts with SPRY1%2C SPRY2%2C and SPRY4 | |
Tgene | CAV1 | chr17:882559 | chr7:116166579 | ENST00000393468 | 0 | 3 | 167_178 | 0 | 148.0 | Region | Interacts with SPRY1%2C SPRY2%2C SPRY3 and SPRY4 | |
Tgene | CAV1 | chr17:882559 | chr7:116166579 | ENST00000393468 | 0 | 3 | 2_94 | 0 | 148.0 | Region | Required for homooligomerization | |
Tgene | CAV1 | chr17:882559 | chr7:116166579 | ENST00000405348 | 0 | 3 | 131_142 | 0 | 148.0 | Region | Interacts with SPRY1%2C SPRY2%2C SPRY3 and SPRY4 | |
Tgene | CAV1 | chr17:882559 | chr7:116166579 | ENST00000405348 | 0 | 3 | 149_160 | 0 | 148.0 | Region | Interacts with SPRY1%2C SPRY2%2C and SPRY4 | |
Tgene | CAV1 | chr17:882559 | chr7:116166579 | ENST00000405348 | 0 | 3 | 167_178 | 0 | 148.0 | Region | Interacts with SPRY1%2C SPRY2%2C SPRY3 and SPRY4 | |
Tgene | CAV1 | chr17:882559 | chr7:116166579 | ENST00000405348 | 0 | 3 | 2_94 | 0 | 148.0 | Region | Required for homooligomerization | |
Tgene | CAV1 | chr17:882559 | chr7:116166579 | ENST00000341049 | 0 | 3 | 126_178 | 10 | 179.0 | Topological domain | Cytoplasmic | |
Tgene | CAV1 | chr17:882559 | chr7:116166579 | ENST00000393467 | 0 | 2 | 126_178 | 0 | 148.0 | Topological domain | Cytoplasmic | |
Tgene | CAV1 | chr17:882559 | chr7:116166579 | ENST00000393467 | 0 | 2 | 2_104 | 0 | 148.0 | Topological domain | Cytoplasmic | |
Tgene | CAV1 | chr17:882559 | chr7:116166579 | ENST00000393468 | 0 | 3 | 126_178 | 0 | 148.0 | Topological domain | Cytoplasmic | |
Tgene | CAV1 | chr17:882559 | chr7:116166579 | ENST00000393468 | 0 | 3 | 2_104 | 0 | 148.0 | Topological domain | Cytoplasmic | |
Tgene | CAV1 | chr17:882559 | chr7:116166579 | ENST00000405348 | 0 | 3 | 126_178 | 0 | 148.0 | Topological domain | Cytoplasmic | |
Tgene | CAV1 | chr17:882559 | chr7:116166579 | ENST00000405348 | 0 | 3 | 2_104 | 0 | 148.0 | Topological domain | Cytoplasmic |
- In-frame and not-retained protein feature among the 13 regional features. |
Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Protein feature | Protein feature note |
Hgene | NXN | chr17:882559 | chr7:116166579 | ENST00000336868 | - | 1 | 8 | 167_321 | 120 | 436.0 | Domain | Thioredoxin |
Hgene | NXN | chr17:882559 | chr7:116166579 | ENST00000537628 | - | 1 | 8 | 167_321 | 0 | 187.0 | Domain | Thioredoxin |
Hgene | NXN | chr17:882559 | chr7:116166579 | ENST00000575801 | - | 1 | 8 | 167_321 | 0 | 328.0 | Domain | Thioredoxin |
Tgene | CAV1 | chr17:882559 | chr7:116166579 | ENST00000341049 | 0 | 3 | 2_94 | 10 | 179.0 | Region | Required for homooligomerization | |
Tgene | CAV1 | chr17:882559 | chr7:116166579 | ENST00000341049 | 0 | 3 | 2_104 | 10 | 179.0 | Topological domain | Cytoplasmic |
Top |
Fusion Gene Sequence for NXN-CAV1 |
![]() |
>61214_61214_1_NXN-CAV1_NXN_chr17_882559_ENST00000336868_CAV1_chr7_116166579_ENST00000341049_length(transcript)=2848nt_BP=452nt CCCAGCGCCTGCCGCCGACGCCGCCGCCTCCTCCCGCCGCGCGGACCGTGGAGCGGGGTCGCAGCCGCCTGCCCGCCCTGCGGTGGGCCA GGATGTCGGGCTTCCTGGAGGAGCTGCTCGGCGAGAAGCTGGTGACGGGCGGCGGCGAGGAGGTGGACGTGCACTCGCTGGGCGCCCGCG GCATCTCGCTGCTGGGTCTCTACTTCGGCTGCAGCCTCAGCGCCCCCTGCGCGCAGCTCAGCGCCAGCCTGGCCGCCTTCTACGGGCGCC TGCGGGGGGACGCGGCGGCCGGGCCGGGGCCGGGAGCGGGGGCCGGGGCGGCGGCGGAGCCCGAGCCGCGGCGGCGCCTGGAGATCGTCT TCGTGTCCTCGGACCAGGACCAGCGGCAGTGGCAGGACTTCGTGCGGGACATGCCGTGGCTGGCGCTGCCCTACAAGGAGAAGCACAGGA AGGGACATCTCTACACCGTTCCCATCCGGGAACAGGGCAACATCTACAAGCCCAACAACAAGGCCATGGCAGACGAGCTGAGCGAGAAGC AAGTGTACGACGCGCACACCAAGGAGATCGACCTGGTCAACCGCGACCCTAAACACCTCAACGATGACGTGGTCAAGATTGACTTTGAAG ATGTGATTGCAGAACCAGAAGGGACACACAGTTTTGACGGCATTTGGAAGGCCAGCTTCACCACCTTCACTGTGACGAAATACTGGTTTT ACCGCTTGCTGTCTGCCCTCTTTGGCATCCCGATGGCACTCATCTGGGGCATTTACTTCGCCATTCTCTCTTTCCTGCACATCTGGGCAG TTGTACCATGCATTAAGAGCTTCCTGATTGAGATTCAGTGCATCAGCCGTGTCTATTCCATCTACGTCCACACCGTCTGTGACCCACTCT TTGAAGCTGTTGGGAAAATATTCAGCAATGTCCGCATCAACTTGCAGAAAGAAATATAAATGACATTTCAAGGATAGAAGTATACCTGAT TTTTTTTCCTTTTAATTTTCCTGGTGCCAATTTCAAGTTCCAAGTTGCTAATACAGCAACAATTTATGAATTGAATTATCTTGGTTGAAA ATAAAAAGATCACTTTCTCAGTTTTCATAAGTATTATGTCTCTTCTGAGCTATTTCATCTATTTTTGGCAGTCTGAATTTTTAAAACCCA TTTAAATTTTTTTCCTTACCTTTTTATTTGCATGTGGATCAACCATCGCTTTATTGGCTGAGATATGAACATATTGTTGAAAGGTAATTT GAGAGAAATATGAAGAACTGAGGAGGAAAAAAAAAAAAAAGAAAAGAACCAACAACCTCAACTGCCTACTCCAAAATGTTGGTCATTTTA TGTTAAGGGAAGAATTCCAGGGTATGGCCATGGAGTGTACAAGTATGTGGGCAGATTTTCAGCAAACTCTTTTCCCACTGTTTAAGGAGT TAGTGGATTACTGCCATTCACTTCATAATCCAGTAGGATCCAGTGATCCTTACAAGTTAGAAAACATAATCTTCTGCCTTCTCATGATCC AACTAATGCCTTACTCTTCTTGAAATTTTAACCTATGATATTTTCTGTGCCTGAATATTTGTTATGTAGATAACAAGACCTCAGTGCCTT CCTGTTTTTCACATTTTCCTTTTCAAATAGGGTCTAACTCAGCAACTCGCTTTAGGTCAGCAGCCTCCCTGAAGACCAAAATTAGAATAT CCATGACCTAGTTTTCCATGCGTGTTTCTGACTCTGAGCTACAGAGTCTGGTGAAGCTCACTTCTGGGCTTCATCTGGCAACATCTTTAT CCGTAGTGGGTATGGTTGACACTAGCCCAATGAAATGAATTAAAGTGGACCAATAGGGCTGAGCTCTCTGTGGGCTGGCAGTCCTGGAAG CCAGCTTTCCCTGCCTCTCATCAACTGAATGAGGTCAGCATGTCTATTCAGCTTCGTTTATTTTCAAGAATAATCACGCTTTCCTGAATC CAAACTAATCCATCACCGGGGTGGTTTAGTGGCTCAACATTGTGTTCCCATTTCAGCTGATCAGTGGGCCTCCAAGGAGGGGCTGTAAAA TGGAGGCCATTGTGTGAGCCTATCAGAGTTGCTGCAAACCTGACCCCTGCTCAGTAAAGCACTTGCAACCGTCTGTTATGCTGTGACACA TGGCCCCTCCCCCTGCCAGGAGCTTTGGACCTAATCCAAGCATCCCTTTGCCCAGAAAGAAGATGGGGGAGGAGGCAGTAATAAAAAGAT TGAAGTATTTTGCTGGAATAAGTTCAAATTCTTCTGAACTCAAACTGAGGAATTTCACCTGTAAACCTGAGTCGTACAGAAAGCTGCCTG GTATATCCAAAAGCTTTTTATTCCTCCTGCTCATATTGTGATTCTGCCTTTGGGGACTTTTCTTAAACCTTCAGTTATGATTTTTTTTTC ATACACTTATTGGAACTCTGCTTGATTTTTGCCTCTTCCAGTCTTCCTGACACTTTAATTACCAACCTGTTACCTACTTTGACTTTTTGC ATTTAAAACAGACACTGGCATGGATATAGTTTTACTTTTAAACTGTGTACATAACTGAAAATGTGCTATACTGCATACTTTTTAAATGTA AAGATATTTTTATCTTTATATGAAGAAAATCACTTAGGAAATGGCTTTGTGATTCAATCTGTAAACTGTGTATTCCAAGACATGTCTGTT CTACATAGATGCTTAGTCCCTCATGCAAATCAATTACTGGTCCAAAAGATTGCTGAAATTTTATATGCTTACTGATATATTTTACAATTT TTTATCATGCATGTCCTGTAAAGGTTACAAGCCTGCACAATAAAAATGTTTAACGGTT >61214_61214_1_NXN-CAV1_NXN_chr17_882559_ENST00000336868_CAV1_chr7_116166579_ENST00000341049_length(amino acids)=316AA_BP=148 MPPTPPPPPAARTVERGRSRLPALRWARMSGFLEELLGEKLVTGGGEEVDVHSLGARGISLLGLYFGCSLSAPCAQLSASLAAFYGRLRG DAAAGPGPGAGAGAAAEPEPRRRLEIVFVSSDQDQRQWQDFVRDMPWLALPYKEKHRKGHLYTVPIREQGNIYKPNNKAMADELSEKQVY DAHTKEIDLVNRDPKHLNDDVVKIDFEDVIAEPEGTHSFDGIWKASFTTFTVTKYWFYRLLSALFGIPMALIWGIYFAILSFLHIWAVVP CIKSFLIEIQCISRVYSIYVHTVCDPLFEAVGKIFSNVRINLQKEI -------------------------------------------------------------- |
Top |
Fusion Gene PPI Analysis for NXN-CAV1 |
![]() |
![]() |
Hgene | Hgene's interactors | Tgene | Tgene's interactors |
![]() |
Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Still interaction with |
Tgene | CAV1 | chr17:882559 | chr7:116166579 | ENST00000341049 | 0 | 3 | 82_94 | 10.0 | 179.0 | CAVIN3 | |
Tgene | CAV1 | chr17:882559 | chr7:116166579 | ENST00000393467 | 0 | 2 | 82_94 | 0 | 148.0 | CAVIN3 | |
Tgene | CAV1 | chr17:882559 | chr7:116166579 | ENST00000393468 | 0 | 3 | 82_94 | 0 | 148.0 | CAVIN3 | |
Tgene | CAV1 | chr17:882559 | chr7:116166579 | ENST00000405348 | 0 | 3 | 82_94 | 0 | 148.0 | CAVIN3 |
![]() |
Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Interaction lost with |
![]() |
Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Interaction lost with |
Top |
Related Drugs for NXN-CAV1 |
![]() (DrugBank Version 5.1.8 2021-05-08) |
Partner | Gene | UniProtAcc | DrugBank ID | Drug name | Drug activity | Drug type | Drug status |
Top |
Related Diseases for NXN-CAV1 |
![]() (DisGeNet 4.0) |
Partner | Gene | Disease ID | Disease name | # pubmeds | Source |
Hgene | NXN | C0009402 | Colorectal Carcinoma | 1 | CTD_human |
Hgene | NXN | C0009404 | Colorectal Neoplasms | 1 | CTD_human |
Hgene | NXN | C1849334 | Robinow syndrome, autosomal recessive | 1 | ORPHANET |
Tgene | C0006142 | Malignant neoplasm of breast | 4 | CTD_human;UNIPROT | |
Tgene | C0678222 | Breast Carcinoma | 4 | CTD_human | |
Tgene | C1257931 | Mammary Neoplasms, Human | 4 | CTD_human | |
Tgene | C1458155 | Mammary Neoplasms | 4 | CTD_human | |
Tgene | C4704874 | Mammary Carcinoma, Human | 4 | CTD_human | |
Tgene | C0004238 | Atrial Fibrillation | 3 | CTD_human | |
Tgene | C0235480 | Paroxysmal atrial fibrillation | 3 | CTD_human | |
Tgene | C2585653 | Persistent atrial fibrillation | 3 | CTD_human | |
Tgene | C3468561 | familial atrial fibrillation | 3 | CTD_human | |
Tgene | C0033578 | Prostatic Neoplasms | 2 | CTD_human | |
Tgene | C0340543 | Familial primary pulmonary hypertension | 2 | CTD_human;GENOMICS_ENGLAND;ORPHANET | |
Tgene | C0376358 | Malignant neoplasm of prostate | 2 | CTD_human | |
Tgene | C2675861 | Lipodystrophy, Congenital Generalized, Type 3 | 2 | CTD_human;GENOMICS_ENGLAND | |
Tgene | C3807567 | PARTIAL LIPODYSTROPHY, CONGENITAL CATARACTS, AND NEURODEGENERATION SYNDROME | 2 | CTD_human;GENOMICS_ENGLAND | |
Tgene | C0002152 | Alloxan Diabetes | 1 | CTD_human | |
Tgene | C0011853 | Diabetes Mellitus, Experimental | 1 | CTD_human | |
Tgene | C0011859 | Lipoatrophic Diabetes Mellitus | 1 | ORPHANET | |
Tgene | C0014518 | Toxic Epidermal Necrolysis | 1 | CTD_human | |
Tgene | C0017612 | Glaucoma, Open-Angle | 1 | CTD_human | |
Tgene | C0018800 | Cardiomegaly | 1 | CTD_human | |
Tgene | C0020538 | Hypertensive disease | 1 | CTD_human | |
Tgene | C0023893 | Liver Cirrhosis, Experimental | 1 | CTD_human | |
Tgene | C0024121 | Lung Neoplasms | 1 | CTD_human | |
Tgene | C0024623 | Malignant neoplasm of stomach | 1 | CTD_human | |
Tgene | C0027627 | Neoplasm Metastasis | 1 | CTD_human | |
Tgene | C0036341 | Schizophrenia | 1 | PSYGENET | |
Tgene | C0038325 | Stevens-Johnson Syndrome | 1 | CTD_human | |
Tgene | C0038356 | Stomach Neoplasms | 1 | CTD_human | |
Tgene | C0038433 | Streptozotocin Diabetes | 1 | CTD_human | |
Tgene | C0043094 | Weight Gain | 1 | CTD_human | |
Tgene | C0206138 | CREST Syndrome | 1 | ORPHANET | |
Tgene | C0221032 | Familial generalized lipodystrophy | 1 | ORPHANET | |
Tgene | C0242379 | Malignant neoplasm of lung | 1 | CTD_human | |
Tgene | C0271148 | Secondary Open Angle Glaucoma | 1 | CTD_human | |
Tgene | C0271694 | Familial partial lipodystrophy | 1 | CTD_human | |
Tgene | C0339573 | Glaucoma, Primary Open Angle | 1 | CTD_human | |
Tgene | C0596263 | Carcinogenesis | 1 | CTD_human | |
Tgene | C0748540 | Scleroderma, Limited | 1 | ORPHANET | |
Tgene | C0919267 | ovarian neoplasm | 1 | CTD_human | |
Tgene | C1140680 | Malignant neoplasm of ovary | 1 | CTD_human | |
Tgene | C1150929 | 2-oxo-hept-3-ene-1,7-dioate hydratase activity | 1 | GENOMICS_ENGLAND | |
Tgene | C1258104 | Diffuse Scleroderma | 1 | ORPHANET | |
Tgene | C1274933 | Drug-Induced Stevens Johnson Syndrome | 1 | CTD_human | |
Tgene | C1383860 | Cardiac Hypertrophy | 1 | CTD_human | |
Tgene | C1701939 | Familial pulmonary arterial hypertension | 1 | ORPHANET | |
Tgene | C1708349 | Hereditary Diffuse Gastric Cancer | 1 | CTD_human | |
Tgene | C1720859 | Familial Partial Lipodystrophy, Type 1 | 1 | CTD_human | |
Tgene | C1720860 | Familial Partial Lipodystrophy, Type 2 | 1 | CTD_human | |
Tgene | C1720861 | Familial Partial Lipodystrophy, Type 3 | 1 | CTD_human | |
Tgene | C2973725 | Pulmonary arterial hypertension | 1 | GENOMICS_ENGLAND | |
Tgene | C3203102 | Idiopathic pulmonary arterial hypertension | 1 | CTD_human;GENOMICS_ENGLAND | |
Tgene | C3658301 | Mycoplasma-Induced Stevens-Johnson Syndrome | 1 | CTD_human | |
Tgene | C3658302 | Stevens-Johnson Syndrome Toxic Epidermal Necrolysis Spectrum | 1 | CTD_human | |
Tgene | C3809192 | PULMONARY HYPERTENSION, PRIMARY, 3 | 1 | GENOMICS_ENGLAND |